Healthcare
Health
Medical

Fresenius Medical Care

$38.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (0.95%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FMS and other stocks, options, ETFs, and crypto commission-free!

About

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. Read More It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Employees
112,658
Headquarters
Bad Homburg, Hessen
Founded
2006
Market Cap
23.25B
Price-Earnings Ratio
10.12
Dividend Yield
1.40
Average Volume
243.47K
High Today
$38.18
Low Today
$37.89
Open Price
$37.93
Volume
32.77K
52 Week High
$53.40
52 Week Low
$30.99

Collections

Healthcare
Health
Medical
Europe (Non-UK)
Europe

News

ReutersMay 16

Shareholders reproach Germany's Fresenius Medical Care after foreign bribery case

* Fresenius Medical Care AGM held on Thursday * Executive board gets approval rating of 56.81 pct * ISS recommends no confidence vote on U.S. bribery settlement BERLIN, May 16 (Reuters) - Fresenius Medical Care on Thursday became the latest German company to face a reproach from investors, with only a narrow majority of shareholders giving its top management and supervisory board their vote of approval. At the dialysis clinic operator’s annual general meeting, 56.81 percent of shareholders voted in favo...

59
Seeking AlphaMay 16

Fresenius Medical Care goes ex-dividend tomorrow

Fresenius Medical Care (NYSE:FMS) declares $0.452/share annual dividend. Payable May 31; for shareholders of record May 20; ex-div May 17. See FMS Dividend Scorecard, Yield Chart, & Dividend Growth....

37
PR NewswireMay 7

CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance

MONMOUTH JUNCTION, N.J., May 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2019. First Quarter 2019 Financial Results: Total revenue for Q1 2019 was $5.2 million , including both product sales and grant income, compared to $4.9 million...

32

Earnings

$0.48
$0.76
$1.03
$1.31
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Available Jul 30, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.